Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies

NCT04384393 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

B Cell Malignancy

Interventions

BIOLOGICAL: ThisCART19 cells

Sponsor

Fundamenta Therapeutics, Ltd.

Collaborators

[object Object]